布地奈德混悬液雾化吸入在儿童急性喉炎、喉气管支气管炎中的疗效观察

Efficacy of ebulized budesonide inhalation in treatment of acute laryngitis or acute laryngotracheobronchitis in children

目的观察布地奈德？昆悬液治疗儿童急性喉炎、喉气管支气管炎的疗效。方法94例急性喉炎、喉气管支气管炎患儿随机分为观察组51例，治疗组43例。在常规治疗的基础上，观察组予布地奈德混悬液氧气驱动雾化吸入，对照组给予地塞米松氧气驱动雾化吸入，对两组治疗后症状、体征持续时间进行比较。结果治疗2h后观察组的症状评分为（1．55±0．64），显著低于对照组（1．84±0．57，P〈0．OS），但72h后治疗组的好转率以及治愈率分别为13．7％和86．3％，与对照组均无显著差异（14％和86％，均P〈0．05）。结论布地奈德混悬液氧气驱动雾化吸入治疗小儿急性喉炎起效快，能有效缓解喉部炎症，解除喉梗阻，避免全身使用激素的不良反应。

Objective To observe the efficacy of nebulized budesonide （BUD） inhalation in the treatment of acute laryngitis or acute laryngotracheobronchitis in pediatric patients. Methods Ninety-four children with acute laryngitis or acute laryngotracheobronchitis, aged 6 months-5 years, were randomly divided into 2 groups： 51 undergoing inhalation of BUD suspension, 0.5 mg/time b.i.d, for 3-5d （observation group）, and 43 treated with inhalation of dexamethasome （DXM） 0.3N0. 5 m g/kg/d for 3 days in addition to conventional antibiotic or antiviral therapy , .The improvement of clinical manifestations were observed until 72 hours after the beginning of treatment. Results The score of clinical presentations 2 h after the beginning of treatment of the observation group was （1.55 ±0.64）, significantly lower than that of the control group （1.84±0.57, P 〈0.05）. However, there were no significant differences in the improvement rate and cure rate 72 hours after the beginning of treatment between these 2 groups （13.7% vs 14% and 86.3% vs 86% respectively, both P 〉0.05）.Conclusion For the children with acute laryngitis or acute laryngotracheobronchitis in addition to the routine anti-infection treatment inhalation of nenulized BUD is better than inhalation of DXM on improving the clinical manifestations and shortening the course of disease.